The beneficial effects of βARKct were enhanced by co-treatment with metoprolol, suggesting that inhibition of GRK2 provides a better clinical outcome than in HF patients treated only by β-blockers (Harding et al., 2001). The gene discussed is GRK2; the disease is hydrops fetalis.